|
View this as a webpage
Minnesota Department of Health
December 9, 2021
Today, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, authorizing the use of a single booster dose for people 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) also released a media statement: CDC Expands COVID-19 Booster Recommendations to 16- and 17-year-olds.
People 16 and 17 years of age should only receive the Pfizer-BioNTech COVID-19 vaccine as their booster dose, as Pfizer-BioNTech is the only vaccine authorized for use for this age group. Pfizer-BioNTech’s Emergency Use Authorization (EUA) fact sheets for health care providers and for recipients and caregivers have been updated.
Most importantly, do not miss any opportunity to vaccinate people who need the primary series.
Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19.
Additional information will be included in the CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines in the next few days.
Thank you for your continued partnership and the critical role you play in keeping Minnesotans safe!
|
